SEC Filing Summary: Celsus Therapeutics PLC (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Celsus Therapeutics PLC on October 2, 2013. The filing serves to disclose a corporate governance update rather than financial results. The registrant is a foreign private issuer based in London, United Kingdom.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report contains no financial statements or quantitative performance data.
Material Changes
The material change disclosed in this filing is the appointment of Allan Shaw to the Company's board of directors, effective October 2, 2013.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It solely references a press release regarding the board appointment.
Key Facts for Investor Verification
- Confirm the background and qualifications of the new board member, Allan Shaw.
- Verify the effective date of the board appointment (October 2, 2013).
- Note that this filing does not impact the company's financial position or operational results.